Margarida Fátima Neto Espírito-Santo

Prof. Margarida Fátima Neto Espírito-Santo

ABC-RI, Algarve Biomedical Center, Faro, Portugal
+1
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2024 in Pharmacy
Verified
Journal Article
Open access
PDF file
Margarida Fátima Neto Espírito-SantoMargarida Fátima Neto Espírito-Santo
Margarida Fátima Neto Espírito-Santo
SSSancha Santos
Sancha Santos
M. Dulce EstêvãoM. Dulce Estêvão
M. Dulce Estêvão
Medication adherence is essential for managing chronic diseases and achieving optimal health outcomes. However, this process is often challenging, particularly for patients with complex care needs. Informal caregivers play a pivotal role in supporting medication management, but they may face resource limitations and a lack of necessary support. Digital health tools offer a promising avenue to enhance medication adherence by providing reminders, education, and remote monitoring capabilities. This scoping review aimed to identify and evaluate digital solutions available to informal caregivers for improving medication adherence. A systematic search of PubMed and Web of Science was conducted using relevant keywords. Four studies were included in the review, examining a variety of digital tools including mobile apps, SMS messaging, and wearable devices. These tools demonstrated efficacy in improving medication adherence, managing disease symptoms, and enhancing quality of life for patients and caregivers. Digital health interventions hold the potential to revolutionize medication adherence among chronic disease patients. By empowering informal caregivers, these tools can bridge the gaps in medication management and contribute to better health outcomes. Further research is warranted to optimize the design, implementation, and evaluation of digital interventions for medication adherence.

22 December 2019 in Journal of Evaluation in Clinical Practice
Verified
Journal Article
Closed access
PDF file
Margarida Fátima Neto Espírito-SantoMargarida Fátima Neto Espírito-Santo
Margarida Fátima Neto Espírito-Santo
Tânia NascimentoTânia Nascimento
Tânia Nascimento
EPEzequiel Pinto
Ezequiel Pinto
ASAna Luísa De Sousa-Coelho
Ana Luísa De Sousa-Coelho
JNJeff Newman
Jeff Newman

9 April 2024 in Healthcare
Verified
Journal Article
Open access
PDF file
ABAna Bandarra
Ana Bandarra
CCCésar Costa
César Costa
KAKristina Angelova
Kristina Angelova
LLLília Leonardo
Lília Leonardo
Margarida Fátima Neto Espírito-SantoMargarida Fátima Neto Espírito-Santo
Margarida Fátima Neto Espírito-Santo
Psychotropic drugs (PDs) include anxiolytics, sedatives and hypnotics, antidepressants, and antipsychotics, and they are available as medicines with different safety profiles. Given Portugal’s high anxiolytic consumption and the rising prevalence of mental disorders, safety monitoring is crucial. This study aimed to analyze the individual case safety reports (ICSR) of suspected adverse drug reactions (ADRs) related to PDs, obtained through spontaneous reporting, and recorded in the Portuguese National Pharmacovigilance System between January 2017 and December 2021. This observational and retrospective study analyzed the ICSRs of suspected ADRs to PDs. Most reports pertained to female individuals (67.78%) between 18 and 64 years of age (63.71%). The pharmaceutical industry was the primary source of these reports (62.16%). Antidepressants were responsible for most ICSRs (61.90%). At least one serious ADR was recorded in 58.44% of the reports, and 43.84% of ADRs evolved into “cure”. The most-observed ADRs were nausea (10.92%), dizziness (10.70%), and off-label use (10.30%). In the causality assessment, 45.49% of ADRs were classified as “possible”, and only 4.96% were classified as “definitive”. The current analysis helps to strengthen the safety evidence for PDs. In the future, some measures could be implemented to improve the use of and/or access to PDs, as well as to reinforce the rate of suspected ADR reports within the community, contributing to the safety data available.

1 January 2025 in Journal of Diabetes Research
Verified
Journal Article
Open access
M. Dulce EstêvãoM. Dulce Estêvão
M. Dulce Estêvão
Mónica Alexandra Teotónio FernandesMónica Alexandra Teotónio Fernandes
Mónica Alexandra Teotónio Fernandes
ASAna Luísa De Sousa-Coelho
Ana Luísa De Sousa-Coelho
Margarida Fátima Neto Espírito-SantoMargarida Fátima Neto Espírito-Santo
Margarida Fátima Neto Espírito-Santo
Tânia NascimentoTânia Nascimento
Tânia Nascimento
Cardiovascular disease (CVD) and diabetes mellitus represent major global health challenges, frequently co‐occurring and mutually exacerbating. Telehealth interventions offer a promising approach for their management, with potential to improve patient outcomes, enhance access to care, and increase cost‐effectiveness. This review synthesized existing evidence from randomized controlled trials (RCTs) and observational studies to evaluate the effectiveness of telehealth interventions for the management of diabetes, focusing on CVD risk, and to identify critical research gaps. A systematic literature search was conducted across major databases (PubMed, Web of Science, and Scopus) to identify studies meeting predefined eligibility criteria, considering digital tools for remote monitoring, consultation, education, and medication management. After the screening of 3041 articles, six studies met the inclusion criteria. Telehealth interventions utilized a range of digital health tools, including mobile applications, artificial intelligence–powered clinical decision aids, electronic consultations, and integrated remote monitoring platforms. Although direct assessment of composite cardiovascular risk was largely absent, the included studies reported several clinical parameters associated with cardiovascular health, namely, blood pressure, lipid profile, and glycated hemoglobin. Telehealth interventions implemented for individuals with Type 2 diabetes mellitus demonstrated promising potential in improving glycemic control and supporting self‐management. However, their effectiveness in managing broader cardiovascular risk factors remains less clear due to inconsistent reporting and heterogeneous intervention designs.

1 August 2024 in Diabetology
Verified
Journal Article
Open access
PDF file
Tânia NascimentoTânia Nascimento
Tânia Nascimento
Margarida Fátima Neto Espírito-SantoMargarida Fátima Neto Espírito-Santo
Margarida Fátima Neto Espírito-Santo
AGAdriana Gonçalves
Adriana Gonçalves
EPEzequiel Pinto
Ezequiel Pinto
ASAna Luísa De Sousa-Coelho
Ana Luísa De Sousa-Coelho
M. Dulce EstêvãoM. Dulce Estêvão
M. Dulce Estêvão
Metabolic syndrome (MS), a complex pathology with features like abnormal body fat distribution, insulin resistance, and dyslipidaemia, contributes to higher cardiovascular (CV) risk. A cross-sectional study including 87 individuals assessed CV risk score in elderly patients with type 2 diabetes and MS in Algarve, Portugal. The 10-year CV risk score was estimated using the ADVANCE risk score calculator. The reductions in CV risk score were estimated by adjusting the data inputted on the online tool to achieve systolic blood pressure (SBP) <130 or <120 mmHg, and LDL cholesterol <70 mg/dL Beyond waist circumference, the mean number of clinical features of MS was 3.14 ± 0.84, without significant sex differences. The mean CV risk score was 22.5% (CI: 20.3–24.7). Sex-specific analysis showed higher risk score in males (24.2%, CI: 21.3–27.0) vs. females (19.7%, CI: 16.2–23.3; p = 0.028). Hypothetical risk score reductions show that lowering SBP to <130 mmHg could significantly lower the risk score by an average of 9.2% (CI: 7.7–10.7), whereas 34.5% of the participants would be out of the diagnostic criteria for MS. When comparing each potential intervention with current risk score, all interventions significantly reduce the 10-year CV risk score. The study highlights the potential of blood pressure control in reducing CV risk score and the importance of multifaceted risk score reduction strategies.

1 January 2026 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Open access
FFFrederico Fonseca
Frederico Fonseca
LLLília Leonardo
Lília Leonardo
ABAlexandre Baptista
Alexandre Baptista
LPLiliana Pedro
Liliana Pedro
MPMaria Luísa Pereira
Maria Luísa Pereira
Margarida Fátima Neto Espírito-SantoMargarida Fátima Neto Espírito-Santo
Margarida Fátima Neto Espírito-Santo
Renal cell carcinoma is the most common type of kidney cancer, accounting for approximately 90% of all cases. Pazopanib, a tyrosine kinase inhibitor, has emerged as an effective treatment option for advanced and metastatic renal cell carcinoma, demonstrating progression‐free survival benefits compared to placebo or interferon in previous Phase 3 clinical trials. However, real‐world data on its safety profile remain limited, underscoring the need for observational studies to assess the efficacy and safety of approved treatments in clinical practice. This retrospective observational study aims to evaluate the real‐world safety of pazopanib in patients with advanced renal cell carcinoma, providing clinical safety data from a hospital unit in the Alentejo region, Portugal, between 2015 and 2024. A total of 22 patients were included in the study, with a median age of 69 years (range: 45–86); the majority were male. The results revealed a higher incidence of adverse drug reactions compared to clinical trials, with hematological and hepatic toxicities being the most common. Thrombocytopenia was observed in 81.8% of patients, while hepatic impairment was reported in 68.2%. Dose adjustments due to analytical intolerance were required in 54.5% of cases. The study also assessed drug interactions in eligible participants within a real‐world clinical setting, revealing a high prevalence of potential drug interactions. On average, 1.36 interactions per patient were identified, with 73.3% classified as high‐risk (Category X). These findings highlight the importance of active pharmacovigilance in optimizing drug safety and treatment outcomes. Strategies such as personalized dosing, medication reconciliation, and close monitoring by clinical pharmacists are essential to mitigate risks and improve patient care. The safety profile and tolerability were found to be consistent with that reported in previous pivotal and real‐world evidence studies, underscoring the need for further research to refine treatment protocols and enhance patient outcomes.